Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment

Daan W. Huntjens; Joost W. Vanhommerig; Willem Van De Veen; Mirjam Crul

doi:10.1001/jamaoncol.2023.4821

Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment

Daan W. Huntjens^*
, Joost W. Vanhommerig
, Willem Van De Veen
, Mirjam Crul

^*Corresponding author for this work

Affiliatie VU

Amsterdam UMC - University of Amsterdam
Onze Lieve Vrouwe Gasthuis
Universität Zürich
OLVG Hospital Location Oost
The Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	131-132
Number of pages	2
Journal	JAMA oncology
Volume	10
Issue number	1
Early online date	2024
DOIs	https://doi.org/10.1001/jamaoncol.2023.4821
Publication status	Published - 18 Jan 2024

Access to Document

10.1001/jamaoncol.2023.4821

Cite this

@article{f58eef119cc84c2e897850282a6d72bd,

title = "Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment",

author = "Huntjens, \{Daan W.\} and Vanhommerig, \{Joost W.\} and Veen, \{Willem Van De\} and Mirjam Crul",

note = "Funding Information: Conflict of Interest Disclosures: Dr van de Veen reported grants from Novartis Research Foundation, grants from Promedica Foundation, Switzerland, grants from European Society of Clinical Microbiology and Infectious Diseases, personal fees from Mabylon AG, Switzerland, and grants from EoE Foundation, Switzerland outside the submitted work. No other disclosures were reported.",

year = "2024",

month = jan,

day = "18",

doi = "10.1001/jamaoncol.2023.4821",

language = "English",

volume = "10",

pages = "131--132",

journal = "JAMA oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "1",

}

TY - JOUR

T1 - Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment

AU - Huntjens, Daan W.

AU - Vanhommerig, Joost W.

AU - Veen, Willem Van De

AU - Crul, Mirjam

N1 - Funding Information: Conflict of Interest Disclosures: Dr van de Veen reported grants from Novartis Research Foundation, grants from Promedica Foundation, Switzerland, grants from European Society of Clinical Microbiology and Infectious Diseases, personal fees from Mabylon AG, Switzerland, and grants from EoE Foundation, Switzerland outside the submitted work. No other disclosures were reported.

PY - 2024/1/18

Y1 - 2024/1/18

UR - https://www.scopus.com/pages/publications/85180980423

U2 - 10.1001/jamaoncol.2023.4821

DO - 10.1001/jamaoncol.2023.4821

M3 - Article

C2 - 37917074

SN - 2374-2437

VL - 10

SP - 131

EP - 132

JO - JAMA oncology

JF - JAMA oncology

IS - 1

ER -

Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment

Access to Document

Other files and links

Cite this